SEARCH OUR PAGES

Partnerships

Partnerships

OSE Immunotherapeutics values collaborations and partnerships with pharmaceutical leaders, clinical organizations and academic laboratories as a fundamental element of both its long-term strategy and day-to-day operations.

Sharing knowledge and bringing together key expertise to facilitate the generation of breakthrough discoveries and to ensure the fastest possible delivery of new therapies to patients in need are fundamental to how OSE’s research teams operate.

Having our product development supported by an international network of pharmaceutical, clinical and academic collaborators allows us increased scale and capacity to enhance the value of our assets.

Pharma Partnerships

For OSE Immunotherapeutics, partnerships and out-licensing deals with global pharmaceutical companies represent ways to rapidly advance the clinical development of its product candidates. Selective partnerships represent a key piece of OSE’s business model that can contribute significantly to the cash flow needed to continue discovering and developing new targets and therapeutic candidates. Pharma partnerships can also generate valuable mid- and long-term revenues through milestone payments and royalties.

OSE Immunotherapeutics is actively pursuing a partnership strategy and frequently communicates with potential pharmaceutical partners.

The potential of the Company’s most advanced programs is the basis for strategic partnerships with premier international pharmaceutical companies for the clinical development of key products:

  • With Boehringer Ingelheim: in April 2018, a worldwide license and collaboration agreement was signed to develop OSE-172 in multiple cancer indications;
  • With Servier: in December 2016, a license option agreement covering development and commercialization of OSE-127 was signed targeting both ulcerative colitis and Sjögren’s syndrome.

Each of these agreements was comprised of an initial upfront payment as well as milestone payments and royalties on potential future sales.

Together, existing partnerships represent a potential of up to €1.3 billion of revenue for OSE Immunotherapeutics, demonstrating our expertise discovering new targets and therapies and validating the high quality and potential of our drug candidates.

    • OSE-127

      Servier

    • €10.25 M upfront

      First step option fee, December 2016

    • €30 M

      Second step option fee, Phase 2 completion UC

    • Up to €272 M

      Milestone payments

    • Royalties on sales

    • OSE-172

      Boehringer Ingelheim

    • €15 M upfront

      Upfront payment, April 2018

    • Up to €15 M

      Short term payments, Initiation of Phase 1

    • Up to €1.1 B

      Milestone payments

    • Royalties on sales

Up to €1.3 B

Milestone payments

Royalties on sales

Clinical Partnerships

Two major partnerships have been put in place with international clinical organizations:

GERCOR

With the oncology cooperative group GERCOR, a network of 300 cancer centers in France dedicated to clinical trials in solid cancers, to investigate TEDOPI® alone or in combination with a PD-1 in pancreatic cancer.

Memorial Sloan Kettering Cancer Center

With the Memorial Sloan Kettering Cancer Center in New York to define the efficacy profile and the development strategy for OSE-703 in various solid tumors with Non-Small Cell Lung Cancer (NSCLC) as the primary cancer model.

    • Tedopi®

       

    • Objective

      Phase 2 in pancreatic cancer in combination with PD-1

    • Partners

      300 cancer centers in France

    • Next step

      Phase 2 initiation early 2019

    • OSE-703

       

    • Objective

      Product efficacy profile and development strategy

    • Partner

      Prasad S. Adusumili, M.D., FACS

    • Next step

      Development strategy in NSCLC
      Potential CAR-T

Academic and Public Partnerships

Since its inception, OSE Immunotherapeutics has collaborated with leading academic teams in the fields of immunology and oncology, notably:

In France

with the INSERM (French National Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research) and Nantes University;

In Europe

with the Children’s Cancer Research Institute of Vienna-Austria, the Biomedical Primate Research Center in the Netherlands or Oxford University in the UK;

In the US

with the University of Maryland in Baltimore or the Ben Towne Center for Childhood Cancer Research in Seattle.

In addition to its wide network of collaborations with top academic centers around the world, OSE Immunotherapeutics is involved in various research and development programs conducted within collaborative consortiums, both funded by partner Bpifrance, a French public investment bank, including:
• EFFIMab, to support OSE-127 development until Phase 2 in collaboration with the INSERM and the Nantes University Hospital;
• EFFI-CLIN, to support OSE-172 development up to the end of Phase 1 in collaboration with the European Center for Transplant and Immunotherapy Sciences (CESTI) and Histalim, a company specialized in immunohistochemistry.

    • OSE-127

      EFFIMab

    • Objective

      Clinical development until Phase 2

    • Partners

    • Next step

      Phase 1 initiation in 2018

    • OSE-172

      EFFI-CLIN

    • Objective

      Phase 1

    • Partners

    • Next step

      Phase 1 initiation in Q1 2019

More information about these agreements can be found in Product section of the website as well as in the media section.